What's happening
This bill requires targeted newborn screening for glucose-6-phosphate dehydrogenase deficiency using specific tests in high-risk cases.
Why it matters
Focuses testing on high-risk newborns. Instead of universally screening all newborns, this bill targets glucose-6-phosphate dehydrogenase (G6PD) deficiency testing for infants with specific risk factors, making screening more precise and relevant.
Reduces missed diagnoses in vulnerable groups. By specifying testing for babies with hemolytic anemia, jaundice, or those with family, racial, or ethnic backgrounds known to have higher G6PD deficiency prevalence (such as African, Asian, Mediterranean, or Middle Eastern ancestry), the bill aims to catch cases that might otherwise be overlooked.
Supports timely intervention and better outcomes. Early identification of G6PD deficiency in at-risk infants means that families and healthcare providers can take precautions to prevent severe complications like kernicterus, acute hemolysis, or prolonged jaundice.
Directs the health department to act quickly. The bill requires the commissioner of health to establish regulations and procedures promptly, ensuring these targeted screenings are implemented without delay, which could help save lives and reduce health disparities.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Test Newborns for G6PD
Plain English, a few words. Used as the page title.
Sponsors
No co-sponsors yet.
History
- Signed chap.70
- Delivered to governor
- Returned to senate
- Passed assembly
- Ordered to third reading cal.353
- Substituted for A8836
- Referred to health
- Delivered to assembly
- Passed senateVote 63–0
- Ordered to third reading cal.22
- Referred to rules
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Screen Newborns for G6PD
Assembly Floor Calendar · Sponsor Richard Gottfried
Full text
1 pageUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
7694
IN SENATE
January 7, 2022
Introduced by Sen. RIVERA -- read twice and ordered printed, and when printed to be committed to the Committee on Rules
AN ACT to amend the public health law, in relation to newborn screening for glucose-6-phosphate dehydrogenase deficiency
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Paragraph (j) of subdivision 1 of section 2500-a of the public health law, as added by a chapter of the laws of 2021 amending the public health law relating to newborn screening for adrenoleukodystrophy and glucose-6-phosphate dehydrogenase deficiency, as proposed in legislative bills numbers A. 4572 and S. 4316, is amended to read as follows:
(j) Glucose-6-phosphate dehydrogenase deficiency using a quantitative enzymatic test or other diagnostic test in cases where: the newborn infant presents with hemolytic anemia, hemolytic jaundice, or early-onset increasing neonatal jaundice, that is, jaundice (bilirubin level greater than fortieth percentile for age in hours) persisting beyond the day of birth through the week after birth; the newborn infant has been admitted to the hospital for jaundice following birth; or the biological parent of the newborn infant indicates a family, racial, or ethnic risk of glucose-6-phosphate dehydrogenase deficiency, including having significant African, Asian, Mediterranean, or Middle Eastern ancestry.
§ 2. This act shall take effect on the same date and in the same manner as a chapter of the laws of 2021 amending the public health law relating to newborn screening for adrenoleukodystrophy and glucose-6-phosphate dehydrogenase deficiency, as proposed in legislative bills numbers A. 4572 and S. 4316, takes effect. Effective immediately, the commissioner of health shall make regulations and take other actions reasonably necessary to implement this act on that date.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD00136-02-2
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the public health law, in relation to newborn screening for glucose-6-phosphate dehydrogenase deficiency
Purpose
This is a chapter amendment that makes changes to provisions of L.2021, c.730.
Summary of provisions
The underlying chapter adds glucose-6-phosphate dehydrogenase deficiency (G6PDD) and adrenoleukodystrophy to the statutory list of disorders as part of the State's Newborn Screening Program. This chapter amendment expands on the clinical scenarios that warrant G6PDD testing.
Existing law
None.
Justification
This legislation is a negotiated change to the underlying chapter since it is necessary to provide clinical indications for G6PDD testing so hospitals can test when clinically indicated.
Legislative history
Chapter amendment to Chapter 730 of the Laws of 2021. S.4316 and A.4572 both passed the Senate and Assembly in May and March of 2021, respec- tively.
Fiscal implications
None.
Effective date
This act shall take effect on the same date and in the same manner as a chapter of the laws of 2021 amending the public health law relating to newborn screening for adrenoleukodystrophy and glucose-6-phosphate dehydrogenase deficiency, as proposed in legislative bills numbers A.4572 and S.4316, takes effect. Effective immediately, the commissioner of health shall make regulations and take other actions reasonably necessary to implement this act on that date.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.